COMPARAÇÃO DO PERFIL DE SENSIBILIDADE ANTIFÚNGICA DE ISOLADOS DE CRIPTOCÓCOS DE LESÕES CUTÂNEAS DE PACIENTES DIAGNÓSTICOS DE HIV / AIDS EM UM HOSPITAL PÚBLICO EM SÃO LUÍS - MA

Anna Rhaabe Braga Pinto, Hermerson Sousa Maia, Moysés Silva de Sousa, Eduardo Bouzi Moffa, Silvio Gomes Monteiro, Cristina de Andrade Monteiro

Resumo


Introdução: A Criptococose é uma infecção oportunista do sistema nervoso e respiratório, no entanto, formas dérmicas podem ser manifestadas em pacientes imunossuprimidos. Objetivos: O objetivo deste trabalho foi determinar o perfil de sensibilidade a antifúngicos de isolados de Cryptococcus laurentii provenientes de lesões cutâneas de pacientes diagnosticados com HIV/AIDS. Dados imunológicos e epidemiológicos, a prevalência de lesões micóticas e dos micro-organismos isolados também foram relatados. Materiais e Métodos: As leveduras isoladas foram identificadas pelo sistema automatizado VITEK e o teste de sensibilidade aos antifúngicos foi realizado por meio do ensaio de microdiluição em placas. Fungos filamentosos foram identificados pelo microcultivo. Dados epidemiológicos e imunológicos foram obtidos por meio da análise de prontuários. Resultados: Quarenta e cinco por cento dos pacientes foram portadores do HIV e 22,7% apresentavam AIDS. A maior frequência foi daqueles com carga viral <1000 cópias/mL (38,6%); 35% eram do sexo masculino e 22,2 % do sexo feminino com faixa etária entre 22 a 81 anos. A maioria tinha menos de oito anos de estudo. A lesão mais prevalente foi onicomicose e os fungos filamentosos foram os micro-organismos mais isolados. Dentre as leveduras isolou-se 26% de Candida spp e 4% de Cryptococcus spp. Os isolados de C. laurentii foram sensíveis ao fluconazol, mas dose-dependente ao itraconazol e resistentes a nistatina e anfotericina B. Conclusão: Estes resultados são relevantes porque mostram a necessidade de uma pronta identificação dos micro-organismos e teste de sensibilidade para uma terapia mais adequada e eficiente.


Texto completo:

PDF

Referências


Ajesh, K, Sreejith, K. Cryptococcus laurentii Biofilms: Structure, Development and Antifungal Drug Resistance. Mycopathologia, 2012;174: 409 – 419.

Aller, AI, Martin-Mazuelos, E, Lozano, F, Gomez-Mateos, J, Steele-Moore, L, Holloway, WJ, et al.. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother, 2000; 44(6):1544-1548.

Alves SH, Oliveira LT, Costa JM, Lubeck I, Casali AK, Vainstein MH. In vitro susceptibility to antifungal agents of clinical and environmental Cryptococcus neoformans isolated in Southern of Brazil. Rev Inst Med Trop São Paulo, 2001; 43: 267-270.

Tovosia S, Chen PH, Ko AM, Tu HP, Tsai PC, Ko YC. Prevalence and associated factors of betel quid use in the Solomon Islands: a hyperendemic area for oral and pharyngeal cancer. Am J Trop Med Hyg. 2007;77(3):586-90.

Arajo AJG, Bastos OMP, Souza MAJ, Oliveira JC. Onychomycosis caused by emergent fungi: clinical analysis, diagnosis and revision. An Bras Dermatol, 2003; 78:445-455.

Bauters TG, Swinne D, Boekhout T, Noens L, Nelis HJ. Repeated isolation of Cryptococcus laurentii from the oropharynx of an immunocompromised patient. Mycopathologia 153: 133-135, 2002.

Brasil, Ministério Da Saúde (Br). Secretaria De Vigilância Em Saúde. Programa Nacional De Dst E Aids. Critérios De Definição De Casos De Aids. 2004.

Brito AM, Castilho EA, Szwarcwald CI. Aids E Infecção Pelo Hiv No Brasil: Uma Epidemia Multifacetada. Ver Sociedade Brasileira de Medicina Tropical, 2011; 34(2): 207-217.

Cambuim IIFF, Macedo DPC, Delgado M, Lima KM, Mendes GP, Souza-Mota CM, Lima DMM, Fernandes MJ, Magalhães OMC, Queiroz LA, Neves RP. Clinical and mycological evaluation of onychomycosis among Brazilian HIV/AIDS patients. Revista da Sociedade Brasileira de Medicina Tropical, 2011; 44: 40-42.

Cheng MF, Chiou CC, Liu YC, Wang HZ, Hsieh KS. Cryptococcus laurentii fungemia in a premature neonate. J Clin Microbiol 2001;39:1608-11

CLSI. Clinical and Laboratory Standards Institute. (NCCLS. National Committee for clinical Laboratory Standards). Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeast. Approved standart M27-A2. Wayne, National Committee for clinical Laboratory Standards, 2008;

Coldrion BM, Bergstresser PR. Prevalence and clinical spectrum of skin disease in patients infected with human immunodeficiency virus. Arch Dermatol 1989;125:357-361;

DAHDAH, MJ, SCHER RK. Onychomycosis - an overview. US: Dermatology review; 2006 .

Espinel-ingroff A, Barchiesi F, Hazen KC, Martinez-Suarez JV, Scalise G. Standardization of Antifungal Susceptibility Testing and Clinical Revelance. Med Mycol,1998; 36: 68-78.

Ferreira-Paim K, Andrade-Silva L, Mora DJ, Lages-Silva E, Pedrosa AL, Silva PR, Andrade AA, Silva-Vergara ML. Antifungal susceptibility, enzimatic activity, PCR-fingerprinting and ITS sequencing of environmental Cryptococcus laurentii isolates from Uberaba, Minas Gerais, Brazil. Mycopathologia, 2012; 174: 41-52.

Furman-Kuklinska K, Naumnik B. Mysliwiec M. Fungaemia due to Cryptococcus laurentii as a complication of immunosuppressive therapy --a case report. Adv Med Sci. 2009; 54(1): 116-9.

Garcia-martos P, Noval JF, Garcia-tapia A, Marin P, Puerto JL, Sepulveda A. Sensibilidad a antifúngicos de especies de Cryptococcus de interes clinico. Med Clin, 2002; 119 (6): 211-213.

Health Protection Agency (2010). Investigation Of Dermatological Specimens For Superficial Mycoses National Standard Method BSOP 39 Issue 2. http://www.hpa-standardmethods.org.uk/pdf_sops.asp;

Heitman J, Kozel TR, Kwon-Chung KJ, Perfect JR, and Casadevall A. Cryptococcus: From Human Pathogen to Model Yeast. Washington, D.C., ASM Press, 2011.620pp;

Johnson LB, Bradley SF, Kauffman CA. Fungaemia due to Cryptococcus laurentii and a review of non-neoformans cryptococcaemia. Mycoses, 1998; 41: 277-280.

Kamalam A, Yesudian P, Thambiah AS. Cutaneous infection by Cryptococcus laurentii. Br J Dermatol, 1997; 97:221-223.

Kordossis T, Avlami A, Velegraki A, Stefanou L, Georgakopoulos G, Papalambrou C, Legakis NJ. First report of Cryptococcus laurentii meningitis and a fatal case of Cryptococcus albidus cryptococcaemia in AIDS patients. Med Mycol, 1998; 36:335-339.

Kunova A, Krcmery V. Fungaemia due to thermophilic cryptococci: 3 cases of Cryptococcus laurentii bloodstream infections in cancer patients receiving antifungal. Scand J Infect Dis, 1999; 31:238.

Kulkarni, Sinha, Anandh, Kulkarni A, Sinha M, Anandh U. Primary cutaneous cryptococcosis due to Cryptococcus laurentii in a renal transplant recipient. Saudi J Kidney Dis Transpl 2012;23:102–5.

Lacaz, CS.Guia Para Identificação de Fungos, Actinomicetos e Algas de interesse médico, 8a ed., Sarvier, São Paulo, 1998.

LACAZ CS.; PORTO E. Tratado de Micologia Médica. São Paulo: Editora Sarvier; 2002.

LIMA ACM, COSTA CC, TELES LMR, DAMASCENO AKC, ORIA MOB. Avaliação epidemiológica da prevenção da transmissão vertical do HIV. Acta Paul Enferm, 2012; 27:311-318.

Lortholary O, Poizat G, Zeller V. Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy.AIDS 2006;20:1764-7.

Manfredi R, Fulgaro C, Sabbatani S, Legnani G, Fasulo G. Emergence of amphotericin B-resistant Cryptococcus laurentii meningoencephalitis shortly after treatment for Cryptococcus neoformans meningitis in a patient with AIDS. AIDS Patient Care STDS, 2006; 20: 227-232.

McCurdy LH, Morrow JD. Ventriculitis due to Cryptococcus uniguttulatus. South Med J, 2001;94:65-6.

McGinnis MR. Laboratory handbook of Medical Mycology. Academic Press, New York, 1980.

MICELI MH, DÍAZ JA, LEE SA. Emerging opportunistic yeast infections. Lancet Infecct Dis, 2011; 11:142-51.

MOLINA-LEYVA A, RUIZ-CARRASCOSA JC, LEYVA-GARCIA A, HUSEIN-ELAHMED H. Cutaneous Cryptococcus laurentii infection in na immunocompetent child. International Journal of Infectious Diseases, 2013; 17: 1232-1233.

Monteiro-Neto V, Bando SY, Moreira-Filho CA, Girón JA. Characterization of an outer membrane protein associated with haemagglutination and adhesive properties of enteroaggregative Escherichia coli 0111:H12. Cel Microbiol, 2003;5:533-47.

Moraes EM, Primola NS, Hamdan JS. Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques. Mycoses. 2003;46: 164-168.

Nacher M, Vantilcke V, Mahamat A, Guedj ME, Vaz, T, Randrianjohany A. Increased incidence of cutaneous mycoses after HAART initiation: a benign form of immune reconstitution disease? Research Letters AIDS. 2007; 21:2243–2250.

Pedroso RS, Ferreira JC, Candido RC. In vitro susceptibility to antifungal agents of environmental Cryptococcus spp. isolated in the city of Ribeirão Preto, São Paulo, Brasil. Mem Inst Oswaldo Cruz, 2006; 101:239-243.

Pedroso RS, Ferreira JC, Costa KRC, Candido RC. Evaluation of The Disk Diffusion Method For Testing Fluconazole Susceptibility of Cryptococcus laurentii. Rev Patol Trop Vol, 2013; 42 (1): 42-48.

Peres NTA, Maranhao FCA, Rossi A, Martinez-Rossi NM. Dermatophytes: host-pathogen interaction and antifungal resistance. An Bras Dermatol. 2010;85(5):657-67.

Perfect JR, Dismukes WE, Dromer F, Goldman DL,Graybill JR. Clinical practice guidelines for the management of cryptococcal disease:2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010;50:291-322.

Riddell RW. Permanent stained mycological preparations obtained by slide culture. Mycologia, 1950; 42:265.

Reichenberg F, Habicht JM, Gratwohl A, Tamm M. Diagnosis and treatment of invasive pulmonar aspergillosis in neutropenic patients. Eur Respir J, 2002; 19:743-755.

Rodwell GE, Bayles CL, Towersey L, Aly R. The prevalence of dermatophyte infection in patients infected with human immunodeficiency virus. Int J Dermatol. 2008;47:339-43.

Schmidt BM, Holmes C. Proximal White onychomycosis in na immunocompetent patient: A case report. Scientific Researchm Publishing. 2015; 4:41-44.

Subramanian S, Mathai D. Clinical manifestations and management of cryptococcal infection. J Postgrad Med, 2005; 51(1): 521-526.

Schuelter-Trevisol F, Pucci P, Justino AZ, Nicole Pucci. Perfil epidemiológico dos pacientes com HIV atendidos no sul do Estado de Santa Catarina, Brasil Epidemiol. Serv. Saúde, 2010; 22 (1).

Torres SR, Luz AMH. Gestante HIV+ e crianças expostas: estudo epidemiológico da notificação compulsória. Rev Gaúcha Enferm, 2007; 28:505-511.

Vender RB. Lynde CW, Poulin Y.Prevalence and epidemiology of onychomycosis. J Cutan Med Surg, 2006; 10:28-33.

Vermout S, Tabart J, Baldo A, Mathy A, Losson B, Mignon B. Pathogenesis of dermatophytosis. Mycopathologia. 2008;166:267-75;

Vlchkova-Lashkoska M, Kamberova S, Starova A, Goleva-Mishevska L, Tsatsa-Biljanovska N, Janevska V, Petrovska M. Cutaneous Cryptococcus laurentii in a human immunodeficiency virus-negative subject. J Eur Acad Dermatol Venereol, 2004; 18:99-100.

Pappalardo MCSM, Szeszs MW, Martins MA, Baceti LB, Bonfietti LX et al. Susceptibility of clinical isolates of Cryptococcus neoformans to amphotericin B using time-kill methodology. Diag Microbiol and Infect Dis 2009; 64: 146-151.

Park BJ, Wannemuehler KA, Marston BJ, Govender N,Pappas PG. Estimation of the global burden of cryptococcal meningitis among people living with HIV/AIDS. AIDS, 2009;23:525-30.

PORRO AM, YOSHIOKA MCN. Manifestações dermatológicas da infecção pelo HIV. An. bras. Dermatol., Rio de Janeiro,2000; 75(6): 665-691.

Reginaldo SP, Joseane CF, Karen RC, Costa RC. Candido Evaluati on of the disk diffusion method for testing fluconazole susceptibility of Cryptococcus laurentii. Revista de Patologia Tropical, 2013; 42 (1): 42-48.

Shankar EM, Kumarasamy N, Bella D, Renuka S, Kownhar H, Suniti S, Rajan R, Rao UA. Pneumonia and pleural effusion due to Cryptococcus laurentii in a clinically proven case of AIDS. Can Respir J, 2006; 13(5):275-278.




DOI: https://doi.org/10.24863/rib.v10i2.259

Apontamentos

  • Não há apontamentos.